Americans for Safe and Effective Medicines advocates to preserve quality standards for medicines through research, education, and common-sense policy.
Joined March 2026
- Tweets71
- Following107
- Followers12
- Likes0
ASEM applauds @SenatorBanks' leadership and the bipartisan senators calling for stronger action against illegal “research use only” drugs. We urge @FDA to hold the briefing and outline how it will crack down on illegal sellers putting patients at risk. bit.ly/3W213VZ
Diane Kinkade says she could barely get off the couch after her compounded tirzepatide supplier changed. Her pleas for help brought canned responses.
Patients deserve answers—and accountability.
Read more from @AlanaSemuels and @Time: time.com/article/2026/10/07/…
AI-generated “experts.” Promises of the “perfect” body. Unapproved peptides with little safety testing.
In a Harvard Chan interview, S. Bryn Austin highlights the risks to young people. FDA must scrutinize these sellers and enforce the law.
Read more: hsph.harvard.edu/news/peptid…
From fentanyl precursors to unapproved peptides: @WSJ reports that companies indicted over the fentanyl supply chain have moved on to peptides.
FDA, CBP and law enforcement must act to stop illegal imports. Warning letters aren’t enough.
Read more: wsj.com/health/pharma/chines…
Americans for Safe and Effective Medicines retweeted
FDA inspectors found black mold on equipment, significant insect activity in ceilings, and other egregious conditions at two Chinese factories producing active ingredients for compounded GLP-1 drugs. American pharma companies are putting U.S. citizens at risk by depending on China to produce medicine. bloomberg.com/news/articles/…
FDA has already flagged safety risks associated with certain unapproved peptides. Expanding their sale before those risks are understood could put patients in harm's way.
ASEM's Fred H. Mills Jr., PharmD, makes the case for putting patient safety first.
bit.ly/4s9ddIr
ASEM has issued a statement on two deaths involving individuals who reportedly used illicit products sold as retatrutide.
The circumstances remain unclear but we urge @FDA to crack down on illegal sellers exploiting demand for weight-loss treatments.
bit.ly/4yU0coM
FDA inspectors found cleanroom dust, inadequate sterility testing and contamination risks involving tirzepatide at a South Carolina compounding facility.
Patients deserve better. @FDA must ensure corrections and take enforcement action where warranted.
fda.gov/media/194820/downloa…
.@Bloomberg reports that people are using unapproved peptides for memory and focus despite limited safety evidence.
An advisory committee recommendations does not equal FDA approval. Regulators must act against illegal sellers. bloomberg.com/news/articles/…
Following his fireside chat at @BeSafenofakes Conference, ASEM Advisory Board member Dr. Richard Dolinar shares his takeaways on mass-compounded GLP-1s, unapproved drugs and patient safety.
Read more: safeandeffectivemeds.org/202…
Retatrutide is still in clinical trials. The black market is already open for business.
@FDA must act to shut down the illegal retatrutide market.
25+ people sick. At least 3 hospitalized.
The CDC linked the outbreak to compounded injections made with an ingredient intended for dietary supplements—not sterile drugs.
Patients deserve better.
Read more @medpagetoday :medpagetoday.com/publichealt…
An illegal drug seller may now be just a scroll away.
ASEM’s Fred Mills, PharmD, writes in @medcitynews about what that means for patients — and why healthcare providers can be a critical line of defense.
medcitynews.com/2026/09/the-…
Unapproved retatrutide is already reaching U.S. consumers.
ASEM + 19 organizations, physicians and health professionals are urging @FDA to stop illegal imports, target unlawful sellers, and follow warnings with enforcement.
safeandeffectivemeds.org/wp-…
ASEM applauds 20 state AGs for sounding the alarm about risks in the GLP-1 supply chain, including foreign-sourced ingredients with potential ties to fentanyl-related entities.
Stronger oversight and enforcement are critical to protecting patients.
safeandeffectivemeds.org/202…
We're attending the @BeSafenofakes conference at @JohnsHopkinsSPH, where ASEM advisory member Dr. Richard Dolinar is sharing his expertise on the illegal GLP-1 compounding crisis. Join us in the conversation as we share insights from his panel. 🧵
Patients need to be informed about the dangers of buying illegal compounded drugs online, and clinicians and pharmacists can help by talking about the risks.